Shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) dropped 7.7% during trading on Friday . The stock traded as low as $1.69 and last traded at $1.69. Approximately 2,193,789 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 4,654,724 shares. The stock had previously closed at $1.83.
Wall Street Analyst Weigh In
AGEN has been the topic of several recent analyst reports. StockNews.com initiated coverage on shares of Agenus in a research note on Thursday. They issued a “sell” rating on the stock. EF Hutton Acquisition Co. I reaffirmed a “buy” rating and issued a $8.30 price target on shares of Agenus in a research note on Wednesday. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Agenus in a research report on Tuesday, February 28th. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, Agenus has an average rating of “Moderate Buy” and a consensus target price of $7.10.
Agenus Trading Down 7.1 %
The business’s 50-day simple moving average is $2.27 and its 200 day simple moving average is $2.44.
Institutional Inflows and Outflows
Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.